{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:15:55Z","timestamp":1702422955453},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T00:00:00Z","timestamp":1318291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Variations in hospital drug formularies have been reported in Germany and the Netherlands for competitive classes.<\/jats:p><jats:p>\u2022\u2003Since a spill\u2010over effect on the community may be expected, assessment of hospital formularies is needed.<\/jats:p><jats:p>\u2022\u2003No study has yet explored French hospitals' drug formularies.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Large variations in the number and the nature of selected drugs were found among French university hospitals for competitive classes.<\/jats:p><jats:p>\u2022\u2003The wide range in the number of selected drugs suggests an unaccomplished rationalization process by some hospitals.<\/jats:p><jats:p><jats:bold>AIM<\/jats:bold> To give a panorama of the selectivity and agreement of French university hospitals' drug formularies (HDF) for nine competitive classes.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> All university hospitals were asked to send their HDF and selection criteria as of January 2009 for nine competitive pharmacological classes (proton pump inhibitors, serotonin antagonists, low molecular weight heparins, erythropoietins, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, statins, \u03b1\u2010adrenoreceptor antagonists and selective serotonin re\u2010uptake inhibitors). Selectivity of HDF was estimated by the percentage of drug entities selected by the hospital within the pharmacological class. Agreement between hospitals was assessed with modified kappa coefficients for multi\u2010raters.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> Twenty\u2010one out of the 29 hospitals agreed to participate. These hospitals selected between 34% and 63% of the drug entities available for the nine classes, which represented 18 to 35 agents. Regarding the nature of chosen drug entities, the overall level of agreement was \u2018fair\u2019 and varied with pharmacological classes. Selection criteria were sent by only 12 hospitals. The technical component was the most important element in all hospitals. The weight of the economic component varied between 20% and 40% in the tender's grade.<\/jats:p><jats:p><jats:bold>DISCUSSION<\/jats:bold> Large variations were seen in the number and nature of drugs selected by university hospitals which can be attributable to two successive decision\u2010making processes (evaluation by the Drug and Therapeutics Committee followed by the purchasing process).<\/jats:p>","DOI":"10.1111\/j.1365-2125.2011.03997.x","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T09:37:06Z","timestamp":1303810626000},"page":"823-831","source":"Crossref","is-referenced-by-count":11,"title":["Drug selection in French university hospitals: analysis of formularies for nine competitive pharmacological classes"],"prefix":"10.1111","volume":"72","author":[{"given":"Adeline","family":"Gallini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Juillard\u2010Condat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Claude","family":"Saux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Taboulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire et des produits de sant\u00e9.Les ventes de m\u00e9dicaments aux officines et aux h\u00f4pitaux en France: chiffres cl\u00e9s 2008.2009. Available athttp:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/4f3d4a5ef9ebec8bf8feb4bff44ffdb2.pdf(last accessed 15 March 2011)."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199201030-00006"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/56.7.622"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00109.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03718.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050315"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00166.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00001.x"},{"key":"e_1_2_7_10_2","unstructured":"World Health Organisation collaborating centre for drug statistics methodology. ATC \/ DDD Index 2009. Available athttp:\/\/www.whocc.no\/atc_ddd_index\/(last accessed 15 March 2011)."},{"key":"e_1_2_7_11_2","unstructured":"EvainF MinodierC.Les centres hospitaliers universitaires: entre activit\u00e9 de pointe et activit\u00e9 de proximit\u00e9. Un essai de typologie. In: Les \u00e9tablissements de sant\u00e9\u2013 Un panorama pour l'ann\u00e9e 2007. DREES; 2010. p. 11\u201029."},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/001316446002000104"},{"key":"e_1_2_7_13_2","first-page":"212","volume-title":"Statistical Methods for Rates and Proportions","author":"Fleiss JL","year":"1981"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(88)90031-5"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0973-y"},{"key":"e_1_2_7_17_2","volume-title":"Model List of Essential Medicines","author":"World Health Organisation","year":"2009"},{"key":"e_1_2_7_18_2","unstructured":"Haute Autorit\u00e9 de Sant\u00e9.Les inhibiteurs de la pompe \u00e0 protons chez l'adulte.2009. Available athttp:\/\/www.has\u2010sante.fr\/portail\/jcms\/c_812065\/les\u2010inhibiteurs\u2010de\u2010la\u2010pompe\u2010a\u2010protons\u2010chez\u2010l\u2010adulte(last accessed 15 March 2011)."},{"key":"e_1_2_7_19_2","unstructured":"Cour des Comptes.Les d\u00e9penses de m\u00e9dicaments. In: Rapport sur l'application des lois de financement de la s\u00e9curit\u00e9 sociale. 2007. p. 286\u2010306. Available athttp:\/\/www.ccomptes.fr\/fr\/CC\/Publications\u2010RELFSS.html(last accessed 15 March 2011)."},{"key":"e_1_2_7_20_2","first-page":"57","article-title":"[Drug selection for formularies in French hospitals]","volume":"45","author":"Ouachi Z","year":"2010","journal-title":"Pharm Hosp"},{"key":"e_1_2_7_21_2","first-page":"174","article-title":"Formulary decision making: identifying factors that influence P&T committee drug evaluations","volume":"23","author":"Segal R","year":"1988","journal-title":"Hosp Formul"},{"key":"e_1_2_7_22_2","first-page":"570","article-title":"Achat de m\u00e9dicaments : La pond\u00e9ration des crit\u00e8res d'attribution des offres","volume":"479","author":"Juillard\u2010Condat B","year":"2008","journal-title":"Gest Hosp"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510330062035"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02600542"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.3.373"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080086"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.4.429"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2011.03997.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2011.03997.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:22:12Z","timestamp":1697394132000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2011.03997.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1111\/j.1365-2125.2011.03997.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03997.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]}}}